Neurocrine’s Bid for Diurnal Could Snag Phase 3 CAH Drug

By PacConAdmin | August 30, 2022

Neurocrine Biosciences has made a bid for the UK-based Diurnal Group, a move that could pull in a phase 3 candidate for treating congenital adrenal hyperplasia (CAH).
Source: Drug Industry Daily

Posted in Drug Industry Daily